Eclipsys posts revenue growth in 2Q

Eclipsys Corp. says it is "pleased with the progress" it continues to make as it released its financial results of the second quarter.

Revenue climbed to $73.6 million, compared with $63.4 million in the first quarter of 2003. The company also reported a net loss of $10 million, compared with a net loss of 11 million in the year-ago quarter.

According to Paul Ruflin, Eclipsys' president and CEO, the company expects continued revenue over the next two quarters due to the recent launch of the latest release of Sunrise Clinical Manager 3.5 XA.

Around the web

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

Trimed Popup
Trimed Popup